Thread by @SatyshivS

The #CovidVaccine is a $50 Billion opportunity
(Assume 5 Billion people taking vaccines 2 times every year, at $5)

And @BharatBiotech is very well positioned to capture a 10% market share with 1 Billion capacity. So such attacks will only increase.

The Big Pharma Cartel was confident of securing a monopoly on this lucrative opportunity

Pfizer alone has forecasted > $25 Billion revenue from #vaccines this year after selling vaccines worth more than $3.5 Billion in the first quarter.

pharmaceutical-technology.com/features/pfize…

At most, they expected some competition from China. But India? India has been seen as a back office, a mass producer of commodities, not as an innovator or a place that can research, develop vaccines.

That's where @BharatBiotech #covaxine has surprised them.

#IndiaFightsCorona

Bharat Biotech's #CoVaxine has several advantages
-Conventional technology platform unlike novel platform mRNA
-Higher efficacy than Astra Zeneca
-No issues like blood clotting reported even 20 million doses
-Neutralises new variants effectively including B.1.167 and B.1.1.7

- It is cost-effective (priced one-third of #Pfizer)
- It can be stored at 2-8C unlike Pfizer or Moderna that require -80C temperature and therefore suitable for most of the developing world
-Soon launching nasal vaccines, making #Vaccination very easy

pharmabiz.com/NewsDetails.as…

Thanks to early success & financial support from govt, @BharatBiotech has quickly ramped up its production capacity to 1 Billion doses a year to meet not just Indian requirement but build significant presence globally

Big Pharma companies are upset

businesstoday.in/current/corpor…

And @BharatBiotech got the best possible brand ambassador when PM @narendramodi chose to get #vaccinated with #CoVaxine as soon as he was eligible to assure people of the safety of the vaccine when it was under attack by agents of Big Pharma companies.